CorMedix Inc. (CRMD) Cash Flow Statement

The wide gap between net income and operating cash flow, particularly in recent quarters, suggests that non-cash expenses are a major component of the income statement. This pattern is typical for a company with significant intangible assets or post-commercialization accounting adjustments, warranting investigation into the specific drivers of these non-cash items to assess the sustainability of the cash flow profile.

The trajectory shows a clear inflection point in Q1 2025, where FCF turned positive and has since scaled dramatically. This shift from cash burn to substantial cash generation is a critical de-risking event for a biotech company, suggesting the commercial launch has achieved a level of scale that now funds operations and growth with significant surplus.

The large, alternating swings in working capital suggest that cash flow timing is heavily influenced by the collection cycle and payment terms with customers and suppliers. This volatility makes quarterly FCF less predictable and implies that investors should focus on the underlying operating cash flow trend rather than quarter-to-quarter FCF fluctuations.

The consistently low capital intensity suggests CorMedix's commercial operations do not require significant ongoing investment in physical assets. This structure is highly favorable for cash flow generation, as it minimizes the reinvestment needed to sustain or grow the business, allowing for greater capital deployment flexibility.

The initiation of buybacks and a small acquisition are the first signs of capital deployment from the newly generated cash flows. The scale of these activities is modest relative to the $87M quarterly FCF, suggesting management is being prudent in its initial allocation, but investors should monitor how aggressively the company pursues further returns or M&A as cash accumulates.